Louisiana State Employees Retirement System Makes New Investment in Perrigo Company plc $PRGO

Louisiana State Employees Retirement System acquired a new stake in Perrigo Company plc (NYSE:PRGO) during the first quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 61,000 shares of the company’s stock, valued at approximately $655,000.

A number of other large investors have also recently added to or reduced their stakes in PRGO. Amundi grew its stake in Perrigo by 11.7% in the 1st quarter. Amundi now owns 5,292 shares of the company’s stock valued at $148,000 after buying an additional 556 shares during the last quarter. Kestra Investment Management LLC lifted its position in shares of Perrigo by 57.1% during the 2nd quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock worth $47,000 after purchasing an additional 642 shares during the last quarter. Geneos Wealth Management Inc. boosted its stake in Perrigo by 439.1% during the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after purchasing an additional 786 shares during the period. EverSource Wealth Advisors LLC raised its stake in Perrigo by 116.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock valued at $26,000 after purchasing an additional 1,014 shares during the last quarter. Finally, Rafferty Asset Management LLC lifted its stake in shares of Perrigo by 9.7% in the third quarter. Rafferty Asset Management LLC now owns 12,153 shares of the company’s stock valued at $271,000 after buying an additional 1,071 shares during the period. Institutional investors own 95.91% of the company’s stock.

Perrigo Price Performance

PRGO traded up $0.25 during midday trading on Tuesday, hitting $11.34. The company had a trading volume of 137,890 shares, compared to its average volume of 3,208,470. Perrigo Company plc has a twelve month low of $9.23 and a twelve month high of $28.43. The firm’s 50-day simple moving average is $10.87 and its 200-day simple moving average is $12.10. The company has a market capitalization of $1.57 billion, a PE ratio of -0.87, a P/E/G ratio of 1.31 and a beta of 0.51. The company has a debt-to-equity ratio of 1.45, a quick ratio of 1.59 and a current ratio of 2.72.

Perrigo (NYSE:PRGO) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.39 by $0.04. Perrigo had a negative net margin of 43.50% and a positive return on equity of 9.96%. The business had revenue of $841.80 million for the quarter, compared to analysts’ expectations of $1.04 billion. During the same period in the prior year, the firm earned $0.60 earnings per share. Perrigo’s revenue was down 7.2% compared to the same quarter last year. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Equities research analysts predict that Perrigo Company plc will post 2.11 EPS for the current fiscal year.

Perrigo Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 16th. Stockholders of record on Friday, May 29th were paid a dividend of $0.29 per share. This represents a $1.16 annualized dividend and a dividend yield of 10.2%. The ex-dividend date of this dividend was Friday, May 29th. Perrigo’s dividend payout ratio is -8.85%.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Zacks Research upgraded Perrigo from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Weiss Ratings upgraded shares of Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. One research analyst has rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $19.33.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.